Publications
Publications 7701 - 7725 de 33557
| Titre | DOI |
|---|---|
|
Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats L. Richert; A. Baze; C. Parmentier; H.H.J. Gerets; R. Sison-Young; M. Dorau; C. Lovatt; A. Czich; C. Goldring; K. Park; S. Juhila; A.J. Foster; D.P. Williams 2016 |
10.1016/j.toxlet.2016.06.1127 |
|
Cytotoxicity of Labruscol, a New Resveratrol Dimer Produced by Grapevine Cell Suspensions, on Human Skin Melanoma Cancer Cell Line HT-144 L. Nivelle; J. Hubert; E. Courot; N. Borie; J.H. Renault; J.M. Nuzillard; D. Harakat; C. Clement; L. Martiny; D. Delmas; P. Jeandet; M. Tarpin 2017 |
10.3390/molecules22111940 |
|
Czochralski crystal growth and characterization of large langatate (La3Ga5.5Ta0.5O14, LGT) crystals for SAW applications A. Nehari; G. Alombert-Goget; O. Benamara; H. Cabane; M. Dumortier; P. Jeandel; I. Lasloudji; F. Mokhtari; T. Baron; G. Wong; M. Allani; J. Boy; S. Alzuaga; L. Arapan; F. Gegot; T. Dufar; K. Lebbou 2019 |
10.1039/c8ce02157k |
|
CZT SPECT Cardiac Radionuclide Angiography: Feasibility of Data-Driven Respiratory-Motion Gating with REGAT Software D. Daou; R. Sabbah; C. Coaguila; H. Boulahdour 2016 |
|
|
CZT SPECT Cardiac Radionuclide Angiography: Feasibility of Data-Driven Respiratory-Motion Gating with REGAT Software D. Daou; R. Sabbah; C. Coaguila; H. Boulahdour 2016 |
|
|
d Bromate anion reduction: novel autocatalytic (EC'') mechanism of electrochemical processes. Its implication for redox flow batteries of high energy and power densities M.A. Vorotyntsev; A.E. Antipov; D.V. Konev 2017 |
10.1515/pac-2017-0306 |
|
D-2 and H-2 adsorption capacity and selectivity in CHA zeolites: Effect of Si/Al ratio, cationic composition and temperature I. Bezverkhyy; Q. Pujol; C. Dirand; F. Herbst; M. Macaud; J.P. Behat 2020 |
10.1016/j.micromeso.2020.110217 |
|
D-2/H-2 adsorption selectivity on FAU zeolites at 77.4 K: Influence of Si/Al ratio and cationic composition M. Giraudet; I. Bezverkhyy; G. Weber; C. Dirand; M. Macaud; J.P. Bellat 2018 |
10.1016/j.micromeso.2018.05.026 |
|
D-Dimer Use and Pulmonary Embolism Diagnosis in Emergency Units: Why Is There Such a Difference in Pulmonary Embolism Prevalence between the United States of America and Countries Outside USA? G. Pernod; J. Caterino; M. Maignan; C. Tissier; J. Kassis; J. Lazarchick; D.E.T.Study Grp 2017 |
10.1371/journal.pone.0169268 |
|
D. Riethmuller in reply to the article by G. Bleu et al.: Assessment of vacuum-assisted delivery in a Frank breech presentation. Gynecol Obstet Fertil 2015;43:123-7 D. Riethmuller 2015 |
10.1016/j.gyobfe.2015.04.015 |
|
Da Vinci Xi Robot-Assisted Penetrating Keratoplasty J. Chammas; A. Sauer; J. Pizzuto; F. Pouthier; D. Gaucher; J. Marescaux; D. Mutter; T. Bourcier 2017 |
10.1167/tvst.6.3.21 |
|
Dabrafenib and Trametinib combination in real life patients including brain metastases: French experience within MelBase C. Allayous; B. Guillot; D. Rat; L. Mortier; C. Dutriaux; M.T. Leccia; J.P. Lacour; S. Dalle; P. Saiag; M. Beylot-Barry; C. Lok; J. De Quatrebarbes; F. Aubin; T. Lesimple; B. Dreno; R. Porcher; A. Ballon; B. Oriano; C. Lebbe 2017 |
|
|
Dabrafenib and Trametinib combination in real life patients including brain metastases: French experience within MelBase C. Allayous; B. Guillot; D. Rat; L. Mortier; C. Dutriaux; M.T. Leccia; J.P. Lacour; S. Dalle; P. Saiag; M. Beylot-Barry; C. Lok; J. De Quatrebarbes; F. Aubin; T. Lesimple; B. Dreno; R. Porcher; A. Ballon; B. Oriano; C. Lebbe 2017 |
|
|
Daclatasvir and sofosbuvir-induced cutaneous adverse reaction with leukocytoclastic vasculitis lesions: first case report A. Dautriche; A. Minello; H. Cosme; G. Jeudy; C. Leleu; M.H. Aubriot-Lorton; A. Grandvuillemin 2015 |
|
|
Daclatasvir plus sofosbuvir with or without ribavirin in genotype 3 patients from a large French multicenter compassionate use program C. Hezode; V. de Ledinghen; H. Fontaine; F. Zoulim; P. Lebray; N. Boyer; D.G. Larrey; C. Silvain; D. Botta-Fridlund; V. Leroy; M. Bourliere; L. d'Alteroche; I. Fouchard-Hubert; D. Guyader; I. Rosa; E. Nguyen-Khac; V. Di Martino; F. Carrat; L. Fedchuk; R. Akremi; Y. Bennai; J.P. Bronowicki 2015 |
|
|
Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program C. Hezode; V. De Ledinghen; H. Fontaine; F. Zoulim; P. Lebray; N. Boyer; L. Dominique; C. Silvain; D. Botta-Fridlund; V. Leroy; M. Bourliere; L. D'alteroche; I. Hubert-Fouchard; D. Guyader; I. Rosa; E. Nguyen-Khac; V. Di Martino; F. Carrat; L. Fedchuk; R. Akremi; Y. Bennai; J. Bronowicki 2015 |
|
|
Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program C. Hezode; V. De Ledinghen; H. Fontaine; F. Zoulim; P. Lebray; N. Boyer; L. Dominique; C. Silvain; D. Botta-Fridlund; V. Leroy; M. Bourliere; L. D'alteroche; I. Hubert-Fouchard; D. Guyader; I. Rosa; E. Nguyen-Khac; V. Di Martino; F. Carrat; L. Fedchuk; R. Akremi; Y. Bennai; J. Bronowicki 2015 |
|
|
DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 3 INFECTION: INTERIM ANALYSIS OF A FRENCH MULTICENTER COMPASSIONATE USE PROGRAM C. Hezode; V. De Ledinghen; H. Fontaine; F. Zoulim; P. Lebray; N. Boyer; D. Larrey; C. Silvain; D. Botta-Fridlund; V. Leroy; M. Bourliere; L. D'alteroche; I. Hubert-Fouchard; D. Guyader; I. Rosa; E. Nguyen-Khac; V. Di Martino; F. Carrat; L. Fedchuk; R. Akremi; Y. Bennai; J.P. Bronowicki; B.Myers Squibb; A.N.R.S.C.O.22Hepat Cohort 2015 |
10.1016/S0168-8278(15)30159-8 |
|
DACLATASVIR PLUS SOFOSBUVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV INFECTION AND DECOMPENSATED CIRRHOSIS: INTERIM ANALYSIS OF A FRENCH MULTICENTRE COMPASSIONATE USE PROGRAMME V. Leroy; C. Hezode; S. Metivier; M. Tateo; F. Conti; E. Nguyen-Khac; D. Lacoste; J. Vergniol; R. Truchi; D. Guyader; G. Riachi; C. Michau; D. Blaison; F. Oberti; H. Fontaine; V. Di Martino; J.P. Bronowicki; R. Akremi; Y. Bennai; A. Filipovics; G.P. Pageaux 2016 |
10.1016/S0168-8278(16)01622-6 |
|
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme C. Hezode; P. Lebray; V. de Ledinghen; F. Zoulim; V. Di Martino; N. Boyer; D. Larrey; D. Botta-Fridlund; C. Silvain; H. Fontaine; L. d'Alteroche; V. Leroy; M. Bourliere; I. Hubert-Fouchard; D. Guyader; I. Rosa; E. Nguyen-Khac; L. Fedchuk; R. Akremi; Y. Bennai; A. Filipovics; Y. Zhao; J.P. Bronowicki 2017 |
10.1111/liv.13383 |
|
Dactylitis in Early Spondyloarthritis. Baseline Data from a Prospective French National Cohort D. Wendling; C. Prati; A. Saraux; A. Molto; T. Pham; M. Dougados; X. Guillot 2018 |
|
|
DACTYLITIS IN EARLY SPONDYLOARTHRITIS. DATA FROM THE DESIR COHORT D. Wendling; C. Prati; A. Saraux; A. Molto; T. Pham; M. Dougados; X. Guillot 2019 |
10.1136/annrheumdis-2019-eular.3166 |
|
Dactylitis in early spondyloarthritis. Data from the prospective French national cohort DESIR D. Wendling; C. Prati; A. Saraux; A. Molto; T. Pham; M. Dougados; X. Guillot 2020 |
10.1016/j.jbspin.2020.01.003 |
|
Dactylitis Occurrence in Early Spondyloarthritis: Five Years Data from a French National Prospective Cohort D. Wendling; C. Prati; A. Saraux; A. Molto; T. Pham; M. Dougados; X. Guillot 2019 |
|
|
Dactylitis Occurrence in Early Spondyloarthritis: Five Years Data from a French National Prospective Cohort D. Wendling; C. Prati; A. Saraux; A. Molto; T. Pham; M. Dougados; X. Guillot 2019 |